Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026
ZVRA•Commercial context
MIPLYFFA is FDA-cleared for neurological manifestations of NPC in patients aged 2 and older when used with miglustat, underpinning Zevra’s commercial strategy.
Long-term real-world MIPLYFFA findings
Zevra Therapeutics said new long-term real-world findings for MIPLYFFA in Niemann-Pick type C are slated for presentation at the 2026 SSIEM symposium.
Expanded access data indicated sustained disease stabilization over multiple years across children and adults, supporting earlier trial evidence of slower progression.
Compassionate-use experience and tolerability
German compassionate-use experience showed long treatment exposure with no treatment-related discontinuations, reinforcing the drug’s tolerability in routine practice.
Some patients worsened quickly when therapy stopped, a signal that could strengthen the case for continued long-term use in clinical care.
